ARIKACE™ Demonstrates Sustained Benefit In Multiple Studies And Over Multiple Cycles

tD33NAt

Active member
Mar 24, 2008
12,519
0
36
Transave, Inc., reported positive clinical trial results on its lead investigational drug, ARIKACE™ (liposomal amikacin for inhalation), an antibiotic that is entering Phase III development for the treatment of chronic lung infections. The results demonstrate significant clinical benefit and complete the company's Phase II program for the treatment of lung infections due to the bacterium, Pseudomonas aeruginosa in cystic fibrosis (CF) patients...


aCmJe1UMPjo


More...
 


Write your reply...
Back
Top